ImmuPharma plc (AIM:IMM)
London · Delayed Price · Currency is GBP · Price in GBX 3.795
+0.590 (18.41%)
Sep 25, 2026, 11:18 AM GMT
ImmuPharma Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
7
Market Cap
20.04M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 118.35K | -8.32K | -6.57% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Palatin Technologies | 9.76M |
| IXICO | 7.28M |
| SkinBioTherapeutics | 5.23M |
| Fusion Antibodies | 2.11M |
| Arecor Therapeutics | 1.71M |
| Ondine Biomedical | 1.43M |
| Aptamer Group | 1.38M |
| Oxford BioDynamics | 1.20M |
ImmuPharma News
- 10 days ago - ImmuPharma Quarterly report: H1 2026 - Filings
- 1 month ago - AIM Market Roundup: Sunda Energy, Gfinity, Tracsis - The Armchair Trader
- 4 months ago - ImmuPharma Annual report: H2 2025 - Filings
- 4 months ago - ImmuPharma Annual report: H2 2025 - Filings
- 6 months ago - ImmuPharma Transcript: Investor update - Transcripts
- 6 months ago - ImmuPharma Press release: Investor update - Filings
- 6 months ago - ImmuPharma Slides: Investor update - Filings
- 6 months ago - AIM Market Roundup: Tern, T42 IoT, Atlantic Lithium - The Armchair Trader